Posted by Michael Wonder on 06 Nov 2024
Dupixent (dupilumab) approved in the European Union as the first and only medicine for young children with eosinophilic oesophagitis
6 November 2024 - Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year.
Regeneron Pharmaceuticals and Sanofi today announced that the European Commission has approved Dupixent (dupilumab) to treat eosinophilic oesophagitis in children as young as 1 year of age.
